37°C in a CO2 (6.5%) atmosphere for 48 h. The specificity of the cytopathic effect (rounding off of the cells) was confirmed by its neutralization with C. sordellii antiserum (Anaerobes Unit, Institut Pasteur, Paris, France).
Clostridium difficile is the major etiological agent of pseudomembranous colitis, antibiotic-associated diarrhea (AAD), and antibiotic-associated colitis (AAC), especially in elderly and immunocompromised patients (patients with hematologic malignancies or patients undergoing chemotherapy) (7) . Pathophysiological mechanisms of C. difficileassociated intestinal infections lead to release of toxins B (cytotoxin) and A (enterotoxin) (7) .
The purpose of this study was to analyze and compare parameters such as in vitro toxin production, serotypes determined by the technique of Delmee et al. (3) , and antimicrobial susceptibility related to C. difficile strains isolated from patients with AIDS and human immunodeficiency virus (HIV)-negative patients.
Study cohort. The study cohort consisted of 50 patients with AIDS and 49 HIV-negative patients with AAD or AAC whose stools harbored C. difficile but no other enteric pathogen. They were selected at random from all of the cases of C. difficile-associated diarrhea or colitis diagnosed in our laboratory from January to December 1991. Clinical information about diarrhea history, underlying diseases, and associated antimicrobial therapy was obtained by reviews of patients' charts.
Bacterial isolates. Stool specimens were inoculated into a medium selective for C. difficile (TCCA) consisting of brain heart infusion supplemented by 5% defibrinated horse blood, 0.1% sodium taurocholate, 250 mg of cycloserine per liter, and 10 mg of cefoxitin per liter (11) clindamycin) to which C. difficile has shown a wide variation in susceptibility (2). Statistical methods. Differences with group proportions were assessed by the chi-square test adapted to large-scale samples, and comparison of means was performed by Student's t test. Two-tailed tests of significance at P < 0.05 were used to determine statistical significance.
The isolates from AIDS and HIV-negative patients came from 23 and 26 different wards, respectively (corresponding to 9 and 17 different hospitals, respectively), thus excluding a possible nosocomial spread of the organism and an epidemic situation. Patients with AIDS were mostly hospitalized in infectious care units, whereas HIV-negative patients came from intensive care units or gastroenterology and oncology wards.
The mean ages were estimated to be 36 + 9 and 61 + 25 years for patients with AIDS and HIV-negative patients, respectively. These two populations were not similar in regard to sex ratio; males were predominant among patients with AIDS (43 males and 7 females) but not among HIVnegative patients (24 males and 25 females). These differences are mainly due to the epidemiological characteristics of AIDS.
We also determined prior antibiotic therapy received during the 6 weeks preceding the onset of diarrhea or colitis; the mean number of antibiotics received was estimated to be 1.3 per patient in the HIV-negative group versus 2.9 per patient for the AIDS group.
The results of stool cytotoxicity and in vitro toxin production tests are summarized in Table 1 . All toxigenic strains isolated from patients with AIDS and HIV-negative patients released both toxins A and B in vitro. We also found that the stool cytotoxin assay was negative for 11 patients with AIDS and 3 HIV-negative patients, although C. difficile strains isolated from their stools had been shown to be toxigenic in both the in vitro cytotoxin and enterotoxin production tests.
Serotyping of C. difficile isolates from patients with AIDS showed that serogroup C was predominant (66.0% of all strains); this was not the case for isolates from HIV-negative patients (18.4%; P < 0.001). Among isolates from the HIV-negative group, a wide distribution pattern of serotypes A, C, D, G, H, and K was observed ( Table 1) . Resistance of C. difficile strains to the five antibiotics tested was significantly higher among isolates from patients with AIDS than among isolates from HIV-negative patients ( Table 1) .
The aim of this study was to determine whether C. difficile strains isolated from patients with AIDS could be distinguished from strains isolated from HIV-negative patients with regard to toxin production, serogrouping, and antimicrobial susceptibility.
Most C. difficile isolates are toxigenic in both HIVnegative and AIDS patients (89.8 and 88.0%, respectively) and can account for cases of diarrhea or colitis in these patients. Nontoxigenic strains belong to serogroups D (five strains), K (one strain) and A (one strain); their significance remains unclear. Patients with nontoxigenic C. difficile strains can be defined merely as carriers, and their diarrhea or colitis should be explained by other mechanisms. For 14 patients (11 patients with AIDS and 3 HIV-negative patients), we found a discrepancy between a negative stool cytotoxin assay and a positive in vitro toxin production assay. We hypothesize that the in vivo toxin level might be too weak to account for the negative stool cytotoxicity assay but sufficient to induce diarrhea or colitis in patients with previous intestinal mucosal damage (such as AIDS patients with HIV enteropathy or a history of repetitive gastrointestinal infections or patients under chemotherapy). In this case, we surmise that the stool cytotoxicity assay, which is considered the "gold standard" method for detecting C. difficile-associated intestinal diseases, might lack reliability for diagnosis. We 
